查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2030150

乾癬治療市場－全球產業規模、佔有率、趨勢、機會和預測：按治療類型、作用機制、給藥途徑、地區和競爭格局分類，2021-2031年

Psoriasis Drugs Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type of Treatment, By Mechanism of Action, By Route of Administration, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球乾癬治療市場預計將從 2025 年的 223.6 億美元成長到 2031 年的 329.8 億美元，複合年成長率為 6.69%。

這些藥物是專門用於治療乾癬的藥物，而乾癬是一種以皮膚發炎為特徵的慢性自體免疫疾病。市場擴張的主要驅動力是全球盛行率的上升，以及生物目標製劑和創新小分子療法的研發，這些藥物為患者提供了更好的治療效果。此外，公眾意識的提高和診斷工具的改進也促使更多人尋求醫療協助。正如國際銀屑病協會聯盟（IFPA）發布的《2025年全球銀屑病地圖集（第三版）》所述，全球約有4300萬人經專業醫療人員正式確診為銀屑病。

市場概覽
預測期 2027-2031
市場規模：2025年 223.6億美元
市場規模：2031年 329.8億美元
複合年成長率：2026-2031年 6.69%
成長最快的細分市場 口服
最大的市場 北美洲

儘管取得了這些積極進展，但尖端生物製藥療法的高昂成本仍然是市場持續成長的主要障礙。如此高昂的成本對全球患者和醫療保健系統構成重大阻礙，可能妨礙其廣泛應用和市場擴張。在醫療預算有限的地區，這個問題特別突出，導致患者難以獲得這些先進療法。

市場促進因素

全球銀屑病患病率的不斷上升是推動銀屑病治療市場成長的主要因素。隨著患者群體的擴大，對有效治療方案的需求日益成長。這種日益加重的疾病負擔推動了對傳統療法和創新療法的需求。 HCPLive 於 2025 年 11 月發布的一項全球分析印證了這一趨勢，該分析顯示，1990 年至 2021 年間，男性銀屑病年齡調整患病率成長了 10.3%，表明新診斷病例持續增加。新病例和患者總數的持續成長確保了從外用乳膏到複雜系統療法等各種醫療手段的持續需求，最終推動市場擴張。

同時，生物製藥和標靶治療的持續進步正透過提高療效和改善患者的治療效果，對整個產業產生重大影響。這些科學進步正在滿足先前未被滿足的醫療需求，並擴大可用治療方法的範圍。例如，2025年12月，美國國家乾癬基金會發表了TYK2抑制劑deuclavacitinib的長期追蹤研究結果，證實了其持續的臨床價值，結果顯示70%的患者在五年內將乾癬嚴重程度指數（PSARI）維持在75分以下。 Fierce Pharma在2025年10月發布的報告顯示，領先的生物製藥Skyrizi在第三季的銷售額達到47億美元，年增率高達47%，這些先進治療方法的研發和成功上市正在顯著提升整個市場的價值。

市場挑戰

全球銀屑病治療市場擴張的主要障礙是最新生物製藥療法的高昂費用。這種高昂的費用嚴重限制了市場成長，極大地限制了患者獲得治療的機會，也阻礙了治療方法的廣泛應用，尤其是在醫療預算有限的地區。因此，儘管這些療法已被證實有效，但由於其沉重的經濟負擔，患者和醫療機構往往無法獲得這些高效的治療方法。

生物製藥的高昂成本是治療的一大障礙。發表於2025年12月《臨床皮膚病學》雜誌的一項回顧性隊列研究強調了這一問題，結果顯示15.5%的患者在啟動生物製藥治療時面臨諸多障礙，其中許多是由於保險拒付或報銷不足。對於全球許多潛在患者而言，經濟負擔往往超過了醫療效益，這一現實直接阻礙了市場發展，並降低了前沿藥物的普及率。此外，持續和長期治療的需求加劇了經濟負擔，導致治療計劃中斷或無法啟動，最終限制了整體市場規模和收入潛力。

市場趨勢

創新口服小分子藥物的問世，正從根本上改變全球乾癬治療市場，為患者提供比傳統注射療法更方便的選擇。這項變革滿足了患者對微創給藥方式的迫切需求，從而提高了治療依從性，並改善了患者的整體體驗。這些藥物為尋求強效全身治療但又不想承受注射之苦的患者提供了顯著優勢，最終擴大了合格人群，並改變了醫生的處方方式。例如，自2026年1月起，百時美施貴寶公司將透過BMS Patient Connect系統，以每月950美元的價格向合格的患者提供其口服TYK2抑制劑deuclavatinib（Sotyktu）。這比標準定價降價了約86%。這種定價策略顯著提高了藥物的可及性，並促進了這些開創性口服療法的應用。

同時，生物相似藥的日益普及是一個重要的市場趨勢，尤其是在抵消先進生物製藥高昂價格方面。生物相似藥物透過促進市場競爭，有助於降低成本並提高經濟可及性，使更多患者能夠獲得以前因昂貴而難以負擔的有效治療。這種可近性的提高對於圖平衡的國家醫療保健系統至關重要。為了強調這一影響，FirstWord Pharma於2025年4月10日發布的新聞稿詳細介紹了一項由山德士公司資助的題為“IMKASID 2025：研究表明，生物類似藥有望在歐洲市場節省5.26億歐元”的研究。研究預測，UstekinumabUstekinumab的引入，預計三年內為德國、英國和瑞典節省5.26億歐元。這些具有成本效益的替代療法的推出，創造了競爭激烈的市場環境，進一步加速了銀屑病治療藥物的市場滲透。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球銀屑病治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（生物製藥、小分子全身性用藥、局部療法）
    • 作用機轉（TNF-α抑制劑、PDE4抑制劑、白細胞介素抑制劑等）
    • 給藥途徑（口服、注射、外用）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美銀屑病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲銀屑病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區乾癬治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲銀屑病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲乾癬治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球乾癬治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie Inc.
  • Johnson & Johnson
  • Novartis AG
  • Eli Lilly and Company
  • Amgen Inc.
  • UCB SA
  • Bristol Myers Squibb Company
  • Sun Pharmaceutical Industries Ltd.
  • Almirall, SA
  • Boehringer Ingelheim International GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16213

The Global market for psoriasis medications is expected to expand from USD 22.36 billion in 2025 to USD 32.98 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.69%. These drugs are specialized pharmaceutical products designed to manage psoriasis, an ongoing autoimmune disease characterized by skin inflammation. Market expansion is largely driven by the rising incidence of this condition worldwide, alongside ongoing developments in targeted biologics and innovative small-molecule treatments that deliver better results for patients. Additionally, greater public awareness and improved diagnostic tools are increasing the number of individuals pursuing medical care. As noted in the 2025 Global Psoriasis Atlas (Third Edition) by the International Federation of Psoriasis Associations (IFPA), roughly 43 million people globally have been officially diagnosed with psoriasis by a medical professional.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 22.36 Billion
Market Size 2031USD 32.98 Billion
CAGR 2026-20316.69%
Fastest Growing SegmentOral
Largest MarketNorth America

In spite of these positive trends, the high expenses linked to cutting-edge biologic therapies present a major obstacle to the market's continued growth. Such steep financial requirements create significant hurdles for patients and medical systems worldwide, which can restrict widespread use and market reach. This issue is particularly pronounced in areas where healthcare funding is limited, ultimately preventing broader access to these advanced treatments.

Market Driver

The rising worldwide occurrence of psoriasis is a primary catalyst for the growth of the psoriasis drugs market, as a broader patient demographic requires effective therapeutic options. This escalating disease burden drives the need for both traditional and innovative medications. Highlighting this trend, a November 2025 global analysis by HCPLive revealed that the age-standardized incidence rate for men with psoriasis increased by 10.3% from 1990 to 2021, illustrating a steady climb in new diagnoses. The continuous growth in both new cases and the total patient population guarantees ongoing demand for medical treatments, spanning from topical creams to complex systemic therapies, which ultimately fuels market expansion.

At the same time, ongoing breakthroughs in biologic and targeted treatments are deeply impacting the industry by delivering enhanced effectiveness and better health outcomes for patients. These scientific steps forward resolve historically unmet medical needs and broaden the range of available therapies. Illustrating this progress, the National Psoriasis Foundation reported in December 2025 that long-term findings for the TYK2 inhibitor deucravacitinib showed 70% of users sustaining a Psoriasis Area Severity Index score of 75 for five years, confirming lasting clinical value. The development and successful rollout of such sophisticated therapies significantly boost the market's total worth, as evidenced by Fierce Pharma's October 2025 report noting that the leading biologic Skyrizi generated USD 4.7 billion in third-quarter sales, a remarkable 47% increase from the previous year.

Market Challenge

A primary obstacle restraining the global psoriasis drugs market's expansion is the steep price tag tied to modern biologic treatments. These exorbitant costs act as a major roadblock to market growth, actively restricting patient access and wider adoption, especially in areas with limited healthcare funding. Consequently, the heavy economic strain frequently stops both individuals and healthcare providers from utilizing these highly capable therapies, even with their proven ability to deliver superior health results.

The premium pricing of biologics creates substantial barriers to acquiring care. Highlighting this issue, a December 2025 retrospective cohort study in Clinical Dermatology found that 15.5% of individuals faced hurdles when starting biologic therapies, mostly resulting from insurance rejections or coverage gaps. This reality directly stifles market progression by lowering the adoption rate of cutting-edge medications, since financial limitations frequently overshadow the medical advantages for numerous prospective patients worldwide. Furthermore, the need for sustained, long-term therapy worsens the economic pressure, leading to interrupted or uninitiated treatment plans, which ultimately limits overall market capacity and revenue potential.

Market Trends

The introduction of innovative oral small-molecule medications is fundamentally transforming the global psoriasis drugs sector by giving patients easier alternatives to conventional injectable therapies. This evolution meets a vital demand for less intrusive delivery methods, which can boost treatment compliance and enhance the general patient experience. These drugs offer clear benefits for those wanting potent systemic care without the hassle of needles, ultimately broadening the population of eligible patients and shifting how doctors prescribe medications. As an example, beginning in January 2026, Bristol Myers Squibb will make its oral TYK2 inhibitor, deucravacitinib (Sotyktu), available via the BMS Patient Connect system for USD 950 monthly to qualified individuals, marking roughly an 86% reduction from the standard list price. This approach to pricing significantly improves drug availability and encourages the use of these pioneering oral therapies.

At the same time, the growing acceptance of biosimilar medications has become a crucial market trend, especially for offsetting the steep prices of sophisticated biologic therapies. By fostering market competition, biosimilars help lower costs and improve financial accessibility, granting more patients the ability to use effective treatments that were once too expensive. This broadened access is essential for international healthcare systems attempting to balance fiscal constraints with the goal of delivering better patient results. Highlighting this impact, an April 10, 2025, FirstWord Pharma press release detailed a Sandoz-backed study titled 'IMKASID 2025: Study Shows Ustekinumab Biosimilars Could Save €526 Million Across European Markets,' which projected three-year savings of €526 million across Germany, the United Kingdom, and Sweden due to ustekinumab biosimilars. The rollout of these budget-friendly substitutes is driving a highly competitive environment and facilitating deeper market penetration for psoriasis treatments.

Key Market Players

  • AbbVie Inc.
  • Johnson & Johnson
  • Novartis AG
  • Eli Lilly and Company
  • Amgen Inc.
  • UCB S.A.
  • Bristol Myers Squibb Company
  • Sun Pharmaceutical Industries Ltd.
  • Almirall, S.A.
  • Boehringer Ingelheim International GmbH

Report Scope

In this report, the Global Psoriasis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psoriasis Drugs Market, By Type of Treatment

  • Biologic Drugs
  • Small Molecule Systemic Drugs
  • Tropical Therapies

Psoriasis Drugs Market, By Mechanism of Action

  • TNF Alpha Inhibitors
  • PDE4 Inhibitors
  • Interleukin Inhibitors
  • Others

Psoriasis Drugs Market, By Route of Administration

  • Oral
  • Parenteral
  • Topical

Psoriasis Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psoriasis Drugs Market.

Available Customizations:

Global Psoriasis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psoriasis Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies)
    • 5.2.2. By Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, Others)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Topical)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Psoriasis Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Treatment
    • 6.2.2. By Mechanism of Action
    • 6.2.3. By Route of Administration
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Psoriasis Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type of Treatment
        • 6.3.1.2.2. By Mechanism of Action
        • 6.3.1.2.3. By Route of Administration
    • 6.3.2. Canada Psoriasis Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type of Treatment
        • 6.3.2.2.2. By Mechanism of Action
        • 6.3.2.2.3. By Route of Administration
    • 6.3.3. Mexico Psoriasis Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type of Treatment
        • 6.3.3.2.2. By Mechanism of Action
        • 6.3.3.2.3. By Route of Administration

7. Europe Psoriasis Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Treatment
    • 7.2.2. By Mechanism of Action
    • 7.2.3. By Route of Administration
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Psoriasis Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type of Treatment
        • 7.3.1.2.2. By Mechanism of Action
        • 7.3.1.2.3. By Route of Administration
    • 7.3.2. France Psoriasis Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type of Treatment
        • 7.3.2.2.2. By Mechanism of Action
        • 7.3.2.2.3. By Route of Administration
    • 7.3.3. United Kingdom Psoriasis Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type of Treatment
        • 7.3.3.2.2. By Mechanism of Action
        • 7.3.3.2.3. By Route of Administration
    • 7.3.4. Italy Psoriasis Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type of Treatment
        • 7.3.4.2.2. By Mechanism of Action
        • 7.3.4.2.3. By Route of Administration
    • 7.3.5. Spain Psoriasis Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type of Treatment
        • 7.3.5.2.2. By Mechanism of Action
        • 7.3.5.2.3. By Route of Administration

8. Asia Pacific Psoriasis Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Treatment
    • 8.2.2. By Mechanism of Action
    • 8.2.3. By Route of Administration
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Psoriasis Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type of Treatment
        • 8.3.1.2.2. By Mechanism of Action
        • 8.3.1.2.3. By Route of Administration
    • 8.3.2. India Psoriasis Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type of Treatment
        • 8.3.2.2.2. By Mechanism of Action
        • 8.3.2.2.3. By Route of Administration
    • 8.3.3. Japan Psoriasis Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type of Treatment
        • 8.3.3.2.2. By Mechanism of Action
        • 8.3.3.2.3. By Route of Administration
    • 8.3.4. South Korea Psoriasis Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type of Treatment
        • 8.3.4.2.2. By Mechanism of Action
        • 8.3.4.2.3. By Route of Administration
    • 8.3.5. Australia Psoriasis Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type of Treatment
        • 8.3.5.2.2. By Mechanism of Action
        • 8.3.5.2.3. By Route of Administration

9. Middle East & Africa Psoriasis Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Treatment
    • 9.2.2. By Mechanism of Action
    • 9.2.3. By Route of Administration
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Psoriasis Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type of Treatment
        • 9.3.1.2.2. By Mechanism of Action
        • 9.3.1.2.3. By Route of Administration
    • 9.3.2. UAE Psoriasis Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type of Treatment
        • 9.3.2.2.2. By Mechanism of Action
        • 9.3.2.2.3. By Route of Administration
    • 9.3.3. South Africa Psoriasis Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type of Treatment
        • 9.3.3.2.2. By Mechanism of Action
        • 9.3.3.2.3. By Route of Administration

10. South America Psoriasis Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Treatment
    • 10.2.2. By Mechanism of Action
    • 10.2.3. By Route of Administration
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Psoriasis Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type of Treatment
        • 10.3.1.2.2. By Mechanism of Action
        • 10.3.1.2.3. By Route of Administration
    • 10.3.2. Colombia Psoriasis Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type of Treatment
        • 10.3.2.2.2. By Mechanism of Action
        • 10.3.2.2.3. By Route of Administration
    • 10.3.3. Argentina Psoriasis Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type of Treatment
        • 10.3.3.2.2. By Mechanism of Action
        • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Psoriasis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Johnson & Johnson
  • 15.3. Novartis AG
  • 15.4. Eli Lilly and Company
  • 15.5. Amgen Inc.
  • 15.6. UCB S.A.
  • 15.7. Bristol Myers Squibb Company
  • 15.8. Sun Pharmaceutical Industries Ltd.
  • 15.9. Almirall, S.A.
  • 15.10. Boehringer Ingelheim International GmbH

16. Strategic Recommendations

17. About Us & Disclaimer